Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anavex Life Sciences Corp. - Common Stock (NQ:AVXL)

2.590 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anavex Life Sciences Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
58 Biggest Movers From Yesterday ↗
Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors.... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) stock moved upwards by 93.55% to $24.33 during Tuesday's regular session. As of 12:30 EST, this security is trading at... 
Via Benzinga
News headline image
35 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares jumped 111.5% to $26.58 after the company announced positive results from its Phase 1b clinical trial of CVL-231... 
Via Benzinga
News headline image
Why This Anavex Life Sciences Analyst Is Lifting Their Price Target ↗
A Cantor Fitzgerald analyst is incrementally bullish on shares of Anavex Life Sciences, Corp (NASDAQ: 
Via Benzinga
News headline image
Anavex Life Sciences Stock Rallies: Technical Levels To Watch ↗
Anavex Life Sciences Corp. (NASDAQ: AVXL) shares traded higher Monday after the company announced ANAVEX2-73, the company’s main pipeline drug, improved both primary... 
Via Benzinga
News headline image
Why Anavex Life Sciences Shares Are Up 17% Today ↗
The biopharma developer dropped some big (but mostly expected) news about the success of one of its drugs. 
Via The Motley Fool
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
Via FinancialNewsMedia
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Intellia Therapeutics (NASDAQ:NTLA 
Via Benzinga
News headline image
44 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
Anavex Life Sciences Stock Jumps As Blarcamesine Shows Convincing Biomarker-Correlating Efficacy Data In Parkinson's Disease Dementia Patients ↗
Anavex Life Sciences Corp (NASDAQ: AVXL) has reported that SIGMAR1 mRNA expression correlates positively with responses in efficacy endpoints in the Phase 2 trial... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion.... 
Via Benzinga
News headline image
60 Biggest Movers From Yesterday ↗
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... 
Via Benzinga
News headline image
3 Top Biotech Stocks to Buy Right Now ↗
These three biotech stocks recently had positive news coming out of phase 2 trials, making them good choices for growth-oriented investors. 
Via The Motley Fool
Alzheimer’s Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027
Via FinancialNewsMedia
Topics Death
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Anavex Life Sciences (NASDAQ:AVXL) stock increased by 17.07% to $25.92 during Tuesday's regular session. As of 12:33 EST, this security is trading at a volume... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers vTv Therapeutics (NASDAQ:VTVT) shares rose 30.08% to $3.07 during Tuesday's pre-market session. The company's market cap stands at $251.7 million. Adial... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
News headline image
48 Biggest Movers From Yesterday ↗
Gainers Lydall, Inc. (NYSE: LDL) shares jumped 85.4% to close at $61.72 on Monday after the company agreed to be acquired by Unifrax for $61.10 per share. New Concept Energy,... 
Via Benzinga
News headline image
Why Anavex Life Sciences Blasted Higher Today ↗
The good news keeps coming for one of the biotech's pipeline drugs. 
Via The Motley Fool
News headline image
10 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Anavex Life Sciences (NASDAQ:AVXL) shares moved upwards by 17.07% to $25.92 during Monday's regular session. Anavex Life Sciences's stock is trading at a... 
Via Benzinga
News headline image
31 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Lydall, Inc. (NYSE: LDL) shares climbed 82.3% to $60.68 after the company agreed to be acquired by Unifrax for $61.10 per share. Raven Industries, Inc. (NASDAQ: RAVN)... 
Via Benzinga
News headline image
How Anavex Extended Its 5-Week Rally On Promising Results In Rett Syndrome ↗
Anavex Life Sciences surged Monday on a positive study in Rett Syndrome, helping AVXL stock extend a triple-digit gain over a five-week rally. 
Via Investor's Business Daily
News headline image
Anavex Life's Rett Syndrome Candidate Shows Promising Biomarker Correlating Efficacy Data ↗
Anavex Life Sciences Corp (NASDAQ: AVXL) has reported a predictive biomarker response from its Phase 2 trial of ANAVEX2-73 (blarcamesine) in adult female patients with... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers MediciNova (NASDAQ:MNOV) shares moved upwards by 50.79% to $5.67 during Monday's pre-market session. The market value of their outstanding shares is at $276.5... 
Via Benzinga
News headline image
48 Biggest Movers From Yesterday ↗
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted the launch of its Amazon Storefront. Orphazyme A/S... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Orphazyme (NASDAQ:ORPH) shares moved upwards by 72.49% to $17.34 during Wednesday's regular session. As of 12:31 EST, Orphazyme's stock is trading at a... 
Via Benzinga
News headline image
44 Biggest Movers From Yesterday ↗
Gainers Alzamend Neuro, Inc. (NASDAQ: ALZN) shares jumped 170% to close at $13.50 on Tuesday after the company priced its IPO at $5 per share. Alfi, Inc. (NASDAQ: ALF) shares... 
Via Benzinga
Topics Initial Public Offering
News headline image
Why Anavex Stock Nearly Round-Tripped Its Double-Digit Gain This Week ↗
Researchers featured a pair of Anavex Life Sciences drugs in a paper on Alzheimer's disease this week, but AVXL stock plunged on Tuesday. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.